2 news items
CORRECTION: Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
BFRI
15 Mar 24
®.Announced first patient dosing in Phase 3 multicenter clinical study of safety and efficacy of Ameluz® and RhodoLED
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update
BFRI
15 Mar 24
®.Announced first patient dosing in Phase 3 multicenter clinical study of safety and efficacy of Ameluz® and RhodoLED
- Prev
- 1
- Next